Welcome to our dedicated page for NVTA news (Ticker: NVTA), a resource for investors and traders seeking the latest updates and insights on NVTA stock.
This page aggregates news and press releases related to Invitae (OTC: NVTA), a medical genetics company that focuses on clinical genetic testing, variant classification, and genomic data research. The news coverage reflects Invitaes role in medical laboratories, health care, and social assistance, as well as its corporate and financial developments.
Company announcements describe Invitae as a provider of genetic information that aims to deliver accurate and actionable results to support medical decision-making. News items include updates on research presented at professional meetings, such as the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting and the American Society of Breast Surgeons Annual Meeting. These stories highlight work on variant reclassification, machine learning models for hereditary cancer and Lynch syndrome genes, and studies of variants of uncertain significance and their impact on clinical management.
Other articles focus on Invitaes technology platforms and data resources, including the Invitae Generation platform and Clinical Variant Modeling, which the company describes as using machine learning and large genomic datasets to improve variant classification. News also covers collaborations with biopharmaceutical partners, such as an agreement with BridgeBio Pharma to use Invitaes rare disease enriched dataset and analytical capabilities for genetics-based drug discovery.
In addition to scientific and product-related updates, the news feed includes major corporate events. These include Invitaes filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey, its court-supervised sale process, and the selection of Labcorp as the winning bidder to acquire substantially all of the companys assets, subject to approvals. Asset transactions involving specific business lines, such as the transfer of certain reproductive health assets to Natera, also appear in coverage.
Investors, clinicians, and others interested in NVTA can use this page to review historical and ongoing developments in Invitaes research activities, technology initiatives, partnerships, restructuring efforts, and asset sales as reported in public news sources.
Invitae Corporation (NYSE: NVTA) announced research revealing that 15.5% of colorectal cancer patients have genetic changes significantly raising cancer risk, particularly in those diagnosed at a younger age. The study, presented at the 2021 ACMG Annual Clinical Genetics Meeting, evaluated genetic testing in 361 patients, finding mutations linked to increased cancer susceptibility. The results emphasize the need for advanced screening strategies and highlight the role of genetic testing in informing treatment decisions and family risk assessments.
Invitae Corporation (NYSE: NVTA) has joined the eMERGE Network, a national initiative funded by the NHGRI, to enhance the integration of genetic data into healthcare. As a clinical affiliate, Invitae will conduct genetic testing for up to 25,000 patients, focusing on hereditary conditions like cancer and heart disease. Participants will receive customized clinical resources, including access to Invitae's chatbot, Gia. This collaboration aims to improve population screening practices, particularly among underrepresented minorities, and deepen the understanding of genetic influences on health.
Invitae (NYSE: NVTA) announced a $1.15 billion investment in convertible senior notes from a group led by SB Management, a Softbank subsidiary, to support growth initiatives. The notes, due in 2028, carry a 1.5% interest rate and have an initial conversion price of $43.18 per share, a 20% premium on the recent average stock price. This funding aims to enhance Invitae's platform and services in clinical genetic sequencing, driving the transition to personalized medicine. The investment is pivotal for expanding their capabilities and improving healthcare outcomes.
Invitae (NYSE: NVTA) announced its definitive agreement to acquire Genosity, a genomics company, for approximately $200 million. The deal includes $120 million in cash and $80 million in Invitae stock. This acquisition aims to enhance Invitae's personalized oncology offerings and leverage Genosity's capabilities in complex sequencing. By integrating Genosity's technology, Invitae expects to speed up the development and accessibility of its Personalized Cancer Monitoring platform, improving patient care globally. The transaction is anticipated to close in Q2 2021.
Invitae Corporation (NYSE: NVTA) has launched a sponsored genetic testing program for patients at risk for neurodegenerative conditions, including Parkinson's disease, ALS, and early-onset Alzheimer's. Available at no charge in the U.S., Canada, Australia, and Brazil, this initiative aims to enhance access to genetic testing, expediting diagnosis and treatment. Eligible individuals aged 18 and over can receive testing if they exhibit symptoms or have a family history. The program also includes genetic counseling for those with positive results, while safeguarding patient privacy.
Invitae Corporation (NYSE: NVTA) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 a.m. Eastern / 7:40 a.m. Pacific. Members of the management team will present during this event, emphasizing the company’s mission to integrate genetic information into mainstream medicine. A live webcast of the presentation will be available on Invitae's investors' website, with a replay accessible shortly after the event's conclusion.
Invitae Corporation (NYSE: NVTA) has integrated Medneon's AI-driven tools to enhance its clinical workflow and patient education in cancer care. This collaboration aims to simplify the process for clinicians in identifying patients eligible for genetic testing and personalizing treatment. Medneon's Predictive Risk Assessment™ helps assess cancer risk based on guidelines and personal history, improving preventative care. The initiative supports telemedicine practices, aiming for better patient outcomes through timely genetic insights.
On February 23, 2021, Invitae Corporation (NYSE: NVTA) announced enhancements to its clinical chatbot Gia, aimed at improving telemedicine support for patients and clinicians. The updated Gia will assist in delivering genetic test results and facilitate scheduling with genetic counselors, addressing delays from in-person appointments. Since its launch in 2017, Gia has served over 100,000 patients and maintains a 92% satisfaction rate. This initiative aligns with Invitae's mission to integrate genetics into routine clinical care and tackle disparities in access to genetic information.
Invitae Corporation (NYSE: NVTA) announced its participation in The Cowen 41st Annual Healthcare Conference, scheduled for March 2, 2021 at 2:50 p.m. Eastern. The presentation aims to highlight the company's mission to integrate genetic information into mainstream healthcare, improving access and affordability. A live webcast of the event will be available on the company's investors page, with a replay accessible afterwards. Invitae focuses on unifying various genetic tests into a single, efficient service.
